Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 10
Submit an article Journal homepage
90
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry

Efrat Luttwaka Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
View further author information
,
Ariela Noya Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAView further author information
,
Venkatraman Seshanc Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Larry A. Saltzmand The Leukemia and Lymphoma Society, Rye Brook, NY, USAView further author information
&
Lee M. Greenbergerd The Leukemia and Lymphoma Society, Rye Brook, NY, USAView further author information
Pages 1727-1729 | Received 09 Nov 2023, Accepted 13 Mar 2023, Published online: 29 Jun 2023
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

We acknowledge that the Leukemia and Lymphoma Society Registry is supported by BeiGene, Pharmacyclics, an AbbVie Company, Kite, a Gilead Company, and Janssen Biotech.

Author contributors

L.M.G. and L.A.S. designed and conducted the survey and participated in data collection. L.G., A.N., E.L., and V.S. performed the analysis. A.N. and E.L. wrote the manuscript. All authors provided critical feedback and reviewed the final manuscript. A.N. – Grant/Research: Pharmacyclics/AbbVie; Kite/Gilead, Cornerstone. Consultant: Janssen, Morphosys, Cornerstone, Epizyme, EUSA, Recordati, TG therapeutics, ADC therapeutics, AstraZeneca, Kite/Gilead, Honoraria: Pharmacyclics/AbbVie.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was supported by the Leukemia and Lymphoma Society.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.